{"id":"monotherapy-etoricoxib","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Edema"},{"rate":null,"effect":"Dyspepsia"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL416146","moleculeType":"Small molecule","molecularWeight":"358.85"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Etoricoxib is a selective COX-2 inhibitor that preferentially blocks the COX-2 enzyme over COX-1, thereby reducing the synthesis of pro-inflammatory prostaglandins while sparing the protective effects of COX-1-derived prostaglandins in the gastrointestinal tract and kidneys. This selective inhibition provides anti-inflammatory, analgesic, and antipyretic effects with a potentially improved gastrointestinal safety profile compared to non-selective NSAIDs.","oneSentence":"Etoricoxib selectively inhibits cyclooxygenase-2 (COX-2) to reduce prostaglandin production and inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:21:59.674Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Osteoarthritis"},{"name":"Acute pain"},{"name":"Ankylosing spondylitis"}]},"trialDetails":[{"nctId":"NCT07328022","phase":"PHASE3","title":"Efficacy and Safety of Etoricoxib/Betamethasone Combination in Acute Bursitis, Tendinitis and Synovitis","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2025-05-14","conditions":"Bursitis, Tendinitis, Synovitis","enrollment":89},{"nctId":"NCT01344720","phase":"PHASE4","title":"Evaluation of the Efficacy and Tolerability of Etoricoxib Monotherapy Versus Combination Oxycodone-etoricoxib in Moderate to Severe Pain From Chronic Low Back Pain","status":"UNKNOWN","sponsor":"Azienda Sanitaria Locale 4, Teramo","startDate":"2011-05","conditions":"Low Back Pain","enrollment":250}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Monotherapy Etoricoxib","genericName":"Monotherapy Etoricoxib","companyName":"Laboratorios Silanes S.A. de C.V.","companyId":"laboratorios-silanes-s-a-de-c-v","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Etoricoxib selectively inhibits cyclooxygenase-2 (COX-2) to reduce prostaglandin production and inflammation. Used for Rheumatoid arthritis, Osteoarthritis, Acute pain.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}